Marcel de Matas is the cofounder and Director of Product Design at Seda Pharmaceutical Development Services, which is focussed on helping biotechnology and drug delivery companies to progress new medicinal products into clinical development and towards commercialisation.
Marcel was formerly a Principal Scientist in Product Development at AstraZeneca where he was focused on advancing and implementing new science and technology to improve and accelerate the development of medicinal products.
He has a degree in chemistry and PhD in physical pharmaceutics and has spent a proportion of his career in industry and in academia. Marcel started his industrial career as a senior scientist in the Respiratory Technology group at Rhone-Poulenc Rorer in 1997 before moving to Zeneca, soon to become AstraZeneca (AZ) in 1999. He initially spent 7 years at AZ, where he led teams working at the Drug Discovery/Development interface and in Late Stage Product Development, whilst also leading specialist drug delivery projects. As a Senior Lecturer in Clinical Pharmaceutics at the University of Bradford, Marcel focused his research on the development and understanding of novel processing and formulation technology, including the evaluation of new methods for manufacturing oral and inhaled dosage forms. His activities were also centred on engineering materials and products to enable improved processing and clinical performance which included the development of methodology for modelling in-vitro in-vivo correlations for inhaled medicines. He was also the Science Lead for a University start-up (Lena Nanoceutics Ltd) which commercialised a novel processing platform for the production of pharmaceutical nanoparticles.
TRANSFORMING MOLECULES INTO VALUED MEDICINES: THE DOMAIN OF THE PHARMACEUTICAL SCIENTIST
Much of the focus of drug development is centred on proving the safety and efficacy of new drugs with significant attention given during drug discovery to the design of the molecule. However, it is the product that the patient actually receives, the regulatory authorities approve, the physician prescribes and the payers reimburse. It is this product, which must deliver the molecule at the right time, the right place and at the right level to deliver a health outcome, which is worthy of registration and reimbursement.
Over the last decade there has been an evolution in the Pharmaceutical Sector focussed on accelerating the development and launch of new medicinal products which address major unmet needs in serious diseases. This has resulted in markedly compressed development timelines which when coupled with substantial constraints on resources and materials puts severe pressure on, Pharmaceutical Scientists, as they must continue to provide robust products and capable manufacturing processes to deliver medicinal products to support clinical development and subsequent commercialisation.
Amongst other disciplines, scientists with a chemistry background play a pivotal role in the development of these drug delivery systems, which provides strong opportunities for future career growth.
This presentation describes some key aspects of pharmaceutical dosage form development and makes reference to examples ranging from the design of particles with enhanced processing characteristics to the evaluation of emerging technologies for product manufacture and the assessment of the linkages between product design and in-vivo performance. Each of these examples have been pertinent to my development as a scientists, but also important in our attempts to transform biologically active chemical entities into products which make a meaningful difference to the health of patients.